Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

 SummaryChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Company
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of pharmaceutical and diagnostic reagents focusing on prescription pharmaceuticals.Its products include respiratory, digestive, urinary, chemotherapy, hormone, vitamins, and metabolic drugs.The company was founded by Ichibei... 
Sector
Pharmaceuticals
Calendar
02/03Earnings Release
More about the company
Surperformance© ratings of ONO PHARMACEUTICAL CO., LT
Trading Rating : Investor Rating :
More Ratings
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Financials ( JPY)
Sales 2015 131 682 M
EBIT 2015 13 250 M
Net income 2015 11 961 M
Finance 2015 164 918 M
Yield 2015 1,77%
Sales 2016 145 412 M
EBIT 2016 -
Net income 2016 15 220 M
Finance 2016 155 054 M
Yield 2016 1,77%
PER 2015 92,31
PER 2016 71,18
EV / Sales 2015 7,85x
EV / Sales 2016 7,18x
Capitalization 1 198 509 M
More Financials
Latest news on ONO PHARMACEUTICAL CO., LT
2h ago ONO PHARMACEUTICAL : And gilead announce exclusive license agreement to develop ..
1d ago Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immun..
2d ago Ono Pharma, Bristol-Myers & Kyowa Hakko Kirin enter pact to condutct phase 1 ..
12/11 Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immun..
12/10 ONO PHARMACEUTICAL : Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-..
12/09 ONO PHARMACEUTICAL : Opdivo (nivolumab) Demonstrates High Overall Response Rate ..
11/18 ONO PHARMACEUTICAL : Study Comparing Opdivo (nivolumab) to Chemotherapy in Treat..
10/30 ONO PHARMACEUTICAL : Phase 2 Objective Response Rates and Survival Data for Opdi..
More news
Sector news
26m agoDJROCHE : Stops Alzheimer Drug Trial; Shows Mixed Results in Breast Cancer Study
1h ago DR REDDY LABORATORIES : Closes the Acquisition of Habitrol® Brand from Novartis
2h ago ROCHE BEARER SHARE : provides update on gantenerumab development programme
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF